BECN1 and chronic myelogenous leukemia, BCR-ABL1 positive: In comparison with CD34− cells, and despite IM treatment, LSCs exhibited lower levels of miR-30a and increased mRNA levels of Beclin 1, which uncovers that targeting miR-30a-mediated Beclin 1 expression, may be crucial to eliminate CML LSCs and prevent disease relapse [154].